Many trials, notably CAR T trials targeting HER2 (NCT04650451), Claudin 18.2 (NCT03874897), GD2 (NCT03373097), PSCA (NCT02744287), and PSMA (NCT04249947, (NCT03089203), reported that patients experienced CRS (regardless of severity). Here, FOLH1 is linked to congenital rubella syndrome.